Mifepristone and Letrozole versus methotrexate for treatment of Ectopic pregnancy - a randomized, controlled non-inferiority trial (MILE) - WML23

Karolinska Institutet0 个研究点目标入组 316 人开始时间: 2023年5月4日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Confirmed ectopic pregnancy, or high suspicion thereof*, in need of treatment. *i.e. empty uterus, pathological hCG dynamic., 18 years old or above, Able to understand verbal and written patient information, Given written consent to participate in the trial

•hCG-levels >5000 IU/L, Heterogenous adnexal mass >35mm, Fetal heart pulsation, Signs of rupture such as large amount of free fluid in the abdomen, severe abdominal pain or hemodynamically unstable, Heterotopic or atypical (cesarean scar pregnancy, cornual, intramural, cervical or abdominal pregnancy) extrauterine pregnancy, Contraindications* to methotrexate, letrozole or mifepristone. * Allergy, severe liver disease (ALT/AST doubled, kidney disease (GFR <60ml/min), bone marrow suppression, active ulcer, severe stomatitis, breastfeeding, severe infection, chronic adrenal insufficiency, porphyria, uncontrolled asthma, active cancer treatment, ongoing treatment for psychosis, anticoagulants, high alcohol consumption

发起方